ASCERTAIN: An open-label, randomized, phase 1, window-of-opportunity study to investigate the biological effects of AZD5305 and darolutamide alone or in combination in men with prostate cancer eligible for radical prostatectomy.
| Autor: | Pacey, Simon, Chi, Kim N., Azad, Arun, Mehra, Niven, Dev, Harveer, Gleave, Martin, Planas, Jacques, Warren, Anne, Harrington, Elizabeth, Albertella, Mark, Squatrito, Massimo, Moore, Luiza, Zhou, TJ, Womersley, Lynsey, Sugibayashi, Ko, Cosulich, Sabina, de Paula, Bruno, Lukacs, Edit, Mateo, Joaquin |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS356-TPS356, 97p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|